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Lycopene and Myocardial Infarction Risk in the EURAMIC Study
Lenore Kohlmeier,1 Jeremy D. Kark,2 Enrique Gomez-Gracia,3 Blaise C. Martin,4 Susan E. Steck,5
Alwine F. M. Kardinaal,6 Jetmund Ringstad,7 Michael Thamm,1 Victor Masaev,8 Rudolf Riemersma,9
Jose M. Martin-Moreno,10 Jussi K. Huttunen,11 and Frans J. Kok6
A multicenter case-control study was conducted to evaluate the relations between antioxidant status
assessed by biomarkers and acute myocardial infarction. Incidence cases and frequency matched controls
were recruited from 10 European countries to maximize the variance in exposure within the study. Adipose
tissue needle aspiration biopsies were taken shortly after the infarction and analyzed for levels of carotenoids
and tocopherols. An examination of colinearity including all covariates and the three carotenoids, a-carotene,
/3-carotene, and lycopene, showed that the variables were sufficiently independent to model simultaneously.
When examined singularly, each of the carotenoids appeared to be protective. Upon simultaneous analyses
of the carotenoids, however, using conditional logistic regression models that controlled for age, body mass
index, socioeconomic status, smoking, hypertension, and maternal and paternal history of disease, lycopene
remained independently protective, with an odds ratio of 0.52 for the contrast of the 10th and 90th percentiles
(95% confidence interval 0.33-0.82, p = 0.005). The associations for a- and /3-carotene were largely
eliminated. We conclude that lycopene, or some substance highly correlated which is in a common food
source, may contribute to the protective effect of vegetable consumption on myocardial infarction risk. Am J
Epidemiol 1997;146:618-26.
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Coronary heart disease remains a major cause of
mortality in developed countries and is increasingly
recognized as an important cause of morbidity in the
developing world as well. A number of important risk
factors for coronary heart disease have been identified
including hypertension, hypercholesterolemia, insulin
resistance, and cigarette smoking. However, these fac-
tors can only partly account for variations in the inci-
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dence of coronary heart disease either between or
within populations (1-3). Studies of lipid metabolism
have suggested that oxidative modifications of low
density lipoprotein accelerate atherogenesis (4-6),
and supplements of the antioxidant vitamin E reduce
the incidence of nonfatal myocardial infarction (7).
Hypothesized methods of promotion of atherogene-
sis by oxidized low density lipoprotein include stim-
ulation of monocyte and platelet adhesion to endothe-
lium, inhibition of vasodilation, stimulation of
synthesis of autoantibodies, and promotion of prolif-
eration of smooth muscle cells leading to the promo-
tion of foam cells and fatty streaks in the arterial
intima (8-10). Natural antioxidants present in the diet
may inhibit the oxidative modification of low density
lipoprotein and slow the progression of atherosclerosis
(11).
Observational epidemiologic studies that explored
the antioxidant vitamin hypothesis using ecologic
studies and cross-sectional studies (12), case-control
studies (13-16), and cohort studies (17, 18) generally
provide evidence supportive of the hypothesis that
some antioxidant vitamins may reduce the risk of
coronary heart disease. However, several large scale
trials have not confirmed a protective effect of )3-
carotene (19-21) and are inconsistent for vitamin E (7,
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19). Ongoing randomized trials of primary (22) and
secondary (23) prevention should elucidate the role of
various doses of antioxidants.
A variety of nutrients have antioxidant activity (e.g.,
carotenoids, vitamin C, tocopherols). Carotenoids are
fat-soluble pigments found in many fresh fruits and
vegetables transported in the human body via lipopro-
teins. They have been shown to have antioxidant abil-
ities in vitro, being most effective as quenchers of
singlet oxygen. /3-Carotene is by far the most widely
studied carotenoid. Increased intake and tissue levels
of j3-carotene have been shown in epidemiologic stud-
ies to be associated with decreased risk of coronary
heart disease (12, 15, 16). The EURAMIC Study sug-
gested that dietary /3-carotene plays a protective role
for myocardial infarction, especially in heavy smokers
(15). However, the Finnish trial of /3-carotene and
a-tocopherol failed to show a reduction in coronary
heart disease in smokers with /3-carotene supplements
(19). The authors inferred from the unexpected find-
ings that "/3-carotene may not be the active . . . com-
ponent of the fruits and vegetables identified as pro-
tective in observational studies" (19, p. 1034).
Similarly, both the CARET and Physician's Health
studies failed to show a chemoprotective effect of
/3-carotene on cardiovascular disease (18, 20, 21).
Thus, the postulated protection of /3-carotene as an
antioxidant against either cancer or cardiovascular dis-
ease remains unproved.
Since supplementation has not been successful,
whereas epidemiologic studies suggest a protective
effect of high vegetable consumption, attention is fo-
cusing on other compounds in vegetables that could
account for their protective effect. For example, other
carotenoids that are present in human tissues in sub-
stantial concentrations are a-carotene and lycopene.
a-Carotene is present in relatively high concentrations
in pumpkins and carrots as is lycopene in tomatoes,
guava, and watermelon. Intakes of these compounds
are often closely correlated with /3-carotene intakes.
This fact might explain why in observational studies
/3-carotene appears to be protective, but in the largest
reported randomized trial it was not (19). It is neces-
sary therefore to assess if there are other micronutri-
ents with antioxidant activity that may play a protec-
tive role against coronary heart disease, especially
other carotenoids apart from /3-carotene (e.g.,
a-carotene and lycopene).
The EURAMIC Study, a multicenter case-control
study, reported on the relation between levels of
a-tocopherol and /3-carotene in adipose tissue and first
acute myocardial infarction (15). This has been
expanded to examine other carotenoids available in
large quantities. We analyzed the levels of a-carotene,
/3-carotene, and lycopene in adipose tissue of cases
and controls of the EURAMIC Study with the aim of
assessing the role of other carotenoids in explaining
the protective association seen between /3-carotene
and myocardial infarction.
MATERIALS AND METHODS
Subject recruitment
The EURAMIC Study design has been described in
detail elsewhere (24). Briefly, centers in 10 countries
recruited incidence cases of first acute myocardial
infarction in men under 70 years of age from coronary
care units of participating hospitals. Of the eligible
cases, 81 percent participated in the study, as did 57
percent of the controls, who consisted of men recruited
from the population in the catchment area of the hos-
pitals providing the acute myocardial infarction cases
(15). The sampling of controls was frequency matched
for age (5-year intervals). The study excluded all per-
sons reporting within the past year a physician-
prescribed change in diet, alteration in dietary vitamin
supplement use, or weight change exceeding 5 kg. A
history of alcohol or drug abuse or of major psychiat-
ric disorder also served as grounds for exclusion. In-
formed consent was obtained for all participants in
accordance with the requirements of responsible com-
mittees on human experimentation. A standard ques-
tionnaire was used in all centers to maintain compa-
rability. Anthropometric measures were taken directly
from all subjects.
Fat aspirate
Subcutaneous adipose tissue was taken from the
buttock by needle aspiration (25). To assist in acquir-
ing the appropriate skills for sampling and to ensure
standardized procedures, a videotape showing the
technique was distributed to all participating centers.
The adipose samples were taken from most cases
within 3 days and often on the day of the infarction.
Samples were collected directly into Vacutainer adapt-
ers (Becton, Dickinson & Company, East Rutherford,
New Jersey) and, without further handling or exposure
to light or air, immediately placed on dry ice or in
liquid nitrogen. They were stored at — 70°C and trans-
ported on dry ice. Quality control samples were in-
cluded in the shipments. Carotenoids and tocopherol
were analyzed using reverse-phase high-performance
liquid chromatography and spectrophotometric detec-
tion.
Carotenoid concentrations were based on the
amount of fat in the sample. This was achieved by
analysis of fatty acids from a split sample from each
individual. After saponification and acidification, the
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free fatty acids were extracted with hexanol and meth-
ylated. Gas-liquid chromatography (HRGC 5300
Mega Series; Carlo Erba, Modena, Italy) with split
injection was conducted in Zeist, Netherlands, using a
30-m-long DB-23 column, inner diameter =
0.253-mm phase layer, and helium as carrier gas, in a
temperature-programmed run. Heptadecanoic acid
was added as an internal standard to the sample prior
to saponification. The addition of three reference sam-
ples taken from a single large specimen of tissue
allowed assessment of within and between run analytic
variation. Approximately equal numbers of samples
from cases and controls were analyzed in each run.
Coefficients of analytic variation for the individual
fatty acids ranged from 13 to 38 percent. The coeffi-
cients of variation for a-carotene, j3-carotene, and
lycopene were 9.0 percent, 6.7 percent, and 8.5 per-
cent, respectively.
Data analyses
Analyses use the pooled data set MI002 from the
EURAMIC Study. An algorithm identified unreliable
assays by comparing fat mass estimated from assay
values with actual tissue sample weight. In addition,
complete chromatographic results were examined for
samples showing extreme or inconsistent carotenoid or
fatty acid values, and these were verified against the
original chromatograms. Subjects with assays deemed
unreliable or with evident chromatographic problems
were excluded from all subsequent analyses. Two
chromatograms showed no peaks for the carotenoids
and were excluded. In another 91 individuals, the total
fat content of the adipose samples, as estimated using
a C17 standard in the chromatograms, was >1 stan-
dard deviation from the total biopsy weight. This
could be due to unreliable biopsy weight measure-
ments or flawed chromatography. Their samples were
also excluded from the final analyses.
A total polyunsaturated fatty acid variable was cre-
ated and includes the three omega-3 fatty acids and
five omega-6 fatty acids measured in the adipose tis-
sue samples.
Initial analyses used simple descriptive statistics to
compare carotenoid levels among cases and controls in
the different centers. The primary analyses were based
on conditional logistic regression modeling after co-
linearity diagnostics to ascertain the independence of
the covariates. Models are conditioned on age and
recruitment center unless otherwise noted. All statis-
tical analyses used SAS version 6.10 software.
Factors included in the logistic regression models in
this process included the known risk factors for car-
diovascular disease: age, body mass index, current and
past smoking, and family history of myocardial infarc-
tion. Other potential confounders from the initial array
of demographic and health history variables were se-
lected for inclusion based upon their statistical signif-
icance and effect on improving the model fit in this
data set. Models were then run with and without
inclusion of other carotenoids simultaneously in the
equation. All variables meeting a statistical signifi-
cance criterion of p = 0.10 were selected for inclusion.
Potential interactions were investigated by stratifica-
tion. To ensure that the model estimates are not un-
stable because of one covariate's being approximately
linearly associated with a combination of the others,
we conducted colinearity diagnostics on each set of
variables entered into a model. The procedure Proc
Reg, using the option "collin" in SAS, was used to
estimate the variance inflation, conditional indices,
and the eigen values (26). If either of the former were
high, or the latter low, the set of variables causing the
colinearity was not used simultaneously in one equa-
tion. This was used, among other things, to test the
modeling of carotenoids simultaneously (27).
Odds ratio measures of association were derived
from the conditional logistic regression models. Odds
ratios were also calculated separately for each center,
conditioned on age. With the exception of quintile
comparisons, all odds ratios represent estimates of the
difference in risk between the 10th and 90th percen-
tiles for each carotenoid, with the percentiles based on
the respective carotenoid's distribution in the control
population.
RESULTS
The distribution of risk factors for myocardial in-
farction in cases and controls is presented in table 1.
The average age of the subjects was 54 years. Men
with acute myocardial infarction were more over-
weight than controls, and a greater proportion were
current smokers who also smoked more heavily, were
more likely to report a maternal and paternal history,
and had a greater prevalence of self-reported hyper-
tension.
The median adipose tissue concentrations of the
three carotenoids for cases and controls by center are
shown in table 2. There was a sixfold difference in the
concentrations of a-carotene among the controls be-
tween centers, a threefold difference in /3-carotene,
and less than a twofold difference in lycopene concen-
trations. Higher a- and /3-carotene concentrations
were found among controls in the northwest countries.
Malaga had the lowest median levels of a-carotene
(0.03 mg/g of fatty acid) and /3-carotene (0.18 mg/g of
fatty acid in controls). The geographic distribution of
lycopene was less consistent, with Helsinki and
Malaga having the lowest mean lycopene concentra-
Am J Epidemiol Vol. 146, No. 8, 1997
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TABLE 1. Distribution
Overall (n = 1,379)
Cases (n = 662)
Controls (n = 717)
of risk factors by disease status, EURAMIC Study, 1991-1992
Age
(years)
Mean SDf
54.0 9.1
54.7* 9.0
53.3* 9.2
Body mass
index
Mean
26.3
26.5*
26.0
SD
3.7
3.9
3.5
Current
smokers
(%)
43
55*
32
Risk factor
No. of
dgarett.es/day
Mean
9.7
13.9*
5.8
SD
14.5
16.6
10.7
Exsmokers
(%)
35
32*
38
Maternal
history
of Mlt
(%)
12
17*
7
Paternal
history
of Ml
(%)
22
26*
19
High
blood
pressure
(%)
21
26*
17
* Significantly different from controls at p < 0.05.
t Ml, myocardial infarction; SD, standard deviation.
TABLE 2. Median adipose tissue carotenoid concentrations of controls by center, EURAMIC Study,
1991-1992
a-Carotene p-Carotene Lycopene a-Tocopherol Body mass
Center (mg/g of (mg/g of (mg/g of (mg/g of Index
fatty add) fatty add) tatty acid) fatty acid) (kg/m*)
Smoker
Poly-
unsaturated
fatty acid
(% of fat)
All (n= 1,387)
Helsinki (n= 120)
Jerusalem (n = 97)
Berlin (n= 162)
Zeist(n=107)
Granada (n = 106)
Edinburgh (n=100)
Sarpsborg(n = 191)
Moscow (n = 186)
Zurich (/)= 123)
Malaga (n= 195)
0.09
0.10
0.09
0.08
0.10
0.04
0.18
0.11
0.11
0.13
0.03
0.45
0.54
0.27
0.46
0.54
0.30
0.61
0.59
0.50
0.54
0.18
0.27
0.23
0.28
0.26
0.27
0.28
0.35
0.30
0.36
0.31
0.21
198
161
124
213
206
205
180
194
243
317
192
25.6
26.6
25.4
25.5
25.4
26.1
25.8
25.1
25.1
26.0
26.9
32
25
36
38
40
52
24
23
38
14
33
14.2
12.2
26.2
12.3
16.2
14.3
12.9
14.8
15.5
13.1
14.3
tions (0.23 mg/g of fatty acid and 0.21 mg/g of fatty
acid, respectively). Moscow had the highest overall
median concentrations of lycopene at 0.36 mg/g of
fatty acid, followed closely by Edinburgh at 0.35 mg/g
of fatty acid. The median carotenoid concentrations by
center for controls are presented in figures 1-3.
Pearson's correlation coefficients were calculated to
assess the relation between the carotenoids and myo-
cardial infarction-associated risk factors. All three
carotenoids were significantly (p < 0.05) negatively
correlated with body mass index (r = —0.22 for
a-carotene, r = -0.23 for /3-carotene, and r = —0.24
for lycopene). a-Carotene and /3-carotene were also
significantly negatively correlated with the number of
cigarettes smoked per day (r = —0.14 for a-carotene,
r = —0.12 for /3-carotene). The carotenoids were
strongly correlated with each other. For a- and /3-
carotene, r = 0.78 {p < 0.0001), for a-carotene and
lycopene, r = 0.60 (p < 0.0001), and for /3-carotene
and lycopene, r - 0.65 (p < 0.0001). Despite these
FIGURE 1. Median /3-carotene concentrations by center, EURAMIC Study, 1991-1992.
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FIGURE 2. Median lycopene concentrations by center, EURAMIC Study, 1991-1992.
strong correlations between the carotenoids, colinear-
ity diagnostics revealed that, in the complete models,
individual carotenoids were adequately separated.
Results of conditional logistic regression (condition-
ing on age and center) after adjustment for body mass
index, socioeconomic status, smoking, family history
of disease, and history of high blood pressure are
presented in table 3. The odds ratios for myocardial
infarction with the continuous carotenoid variables per
unit of change as modeled both separately and simul-
taneously revealed lycopene to be the only carotenoid
with a significant independent association with lower
risk of myocardial infarction. The odds ratio for lyco-
pene, when modeled separately, was 0.50 (95 percent
confidence interval 0.34-0.73) for the contrast be-
tween the 10th and 90th percentiles in this population.
When modeled simultaneously with a- and /3-
carotene, the odds ratio was almost identical, 0.52 (95
percent confidence interval 0.33-0.82). /3-Carotene,
on the other hand, was not significantly inversely
associated with protection against myocardial infarc-
tion (odds ratio = 0.73, 95 percent confidence interval
0.55-0.96) prior to simultaneous modeling, but after
adjustment for other carotenoids, the point estimate of
1.01 (95 percent confidence interval 0.66-1.55) re-
mained insignificantly associated with myocardial in-
farctions. Similarly, a protective association of a-
carotene on its own was virtually eliminated when
modeled together with the other carotenoids.
Table 4 reports the odds ratios for myocardial in-
farction by quintiles of adipose tissue carotenoid con-
centrations, based on the distributions in the control
population, with the bottom fifth serving as the refer-
ent category. Trend analyses showed all three carote-
noids to be protective when modeled separately. In
simultaneous analyses, accounting for all three caro-
tenoids at the same time, no trend toward lower risk
with higher a-carotene levels was seen {p = 0.74).
The trend for /3-carotene remained statistically signif-
icant after inclusion of the other carotenoids in the
0.2
0.15
s
I 0-1
I
0.05
I
• • I
• • I I I
— — •
11
'S </ /S </
FIGURE 3. Median a-carotene concentrations by center, EURAMIC Study, 1991-1992.
Am J Epidemiol Vol. 146, No. 8, 1997
Lycopene and Myocardial Infarction 623
TABLE 3. Conditional odds ratios for myocardial infarction by carotenoid adipose tissue sample
concentration, EURAMIC Study, 1991-1992*
Adipose
concentration a-Carotene
P
value ^Carotene
P
value Lycopene
P
value
Separately
Simultaneously
0.68 (0.49-0.93)t
0.91 (0.58-1.41)
0.02
0.66
0.73 (0.55-0.96)
1.01 (0.66-1.55)
0.03
0.96
0.50 (0.34-0.73)
0.52 (0.33-0.82)
0.003
0.005
* The odds ratios are conditional on age and center; covariates are body mass index, age, center, smoking,
maternal and paternal history of disease, and history of high blood pressure. The odds ratios are based on the
contrast of the 10th and 90th percentiles of the carotenoid from controls in the population at large. All of the
carotenoids are scaled in these models.
t Numbers in parentheses, 95% confidence interval.
TABLE 4. Conditional odds ratios of myocardial infarction associated with quintiles of adipose
carotenoids compared with the lowest quintile, EURAMIC Study, 1991-1992*
Quintile 1
Separately
Simultaneously
Quintile 2
Separately
Simultaneously
Quintile 3
Separately
Simultaneously
Quintile 4
Separately
Simultaneously
Quintile 5
Separately
Simultaneously
p for trend
Separately
Simultaneously
a-Carotenet
1.00
1.00
1.07(0.70-1.63)H
1.18(0.79-1.90)
0.80(0.50-1.30)
1.11 (0.61-2.02)
0.86(0.52-1.40)
1.37(0.71-2.66)
0.52 (0.29-0.91)
1.23(0.56-2.67)
0.31
0.74
p-Carotenef
1.00
1.00
1.07(0.70-1.63)
1.14(0.72-1.67)
0.72(0.45-1.15)
0.82(0.51-1.33)
0.90(0.56-1.45)
1.01 (0.60-1.67)
0.38 (0.22-0.66)
0.47 (0.26-0.99)
0.003
0.023
Lycopene§
1.00
1.00
0.77(0.51-1.17)
0.84(0.54-1.29)
0.56 (0.36-0.87)
0.61 (0.38-0.98)
0.55 (0.35-0.86)
0.61 (0.36-1.03)
0.42 (0.25-0.70)
0.54 (0.29-0.98)
0.006
0.008
* The odds ratios are conditioned on age and center; covariates are body mass index, smoking, maternal and
paternal history of disease, history of high blood pressure, age, and a-tocopherol. The odds ratios are based on
the contrast of the 10th and 90th percentiles of the carotenoid from controls in the population at large. All of the
carotenoids are scaled in these models.
t Median a-carotene levels are 0.03, 0.05, 0.09, 0.13, and 0.24 |ig/g of fat for quintiles 1-5, respectively.
t Median p-carotene levels are 0.14, 0.29,0.44, 0.63, and 1.11 ng/g of fat for quintiles 1-5, respectively.
§ Median lycopene levels are 0.11, 0.20, 0.27, 0.38, and 0.62 ng/g of fat for quintiles 1-5, respectively.
H Numbers in parentheses, 95% confidence interval.
model. However, the association within the upper four
quintiles was not consistent, and only for the fifth
quintile of the /3-carotene distribution was the odds
ratio substantially protective in the simultaneous
model at 0.47 (95 percent confidence interval 0.26-
0.99). Lycopene showed the greatest protective effect
with a tendency toward increasing inverse odds ratios
with increased concentrations, evident in both the sep-
arate and simultaneous models. The probability of the
inverse association's arising by chance is 0.008 (from
the test of trend).
Polyunsaturated fats and carotenoid effects
An examination of the carotenoid interactions with
polyunsaturated fats and acute myocardial infarction
using interaction terms and categorizing polyunsatu-
rated fat levels in adipose tissues by tertiles revealed a
significant interaction (table 5). The protective effect
of lycopene increased at each increasing level of poly-
unsaturated fat and was significant in the individuals
whose adipose tissue contained more than 16.1 percent
of the fat in the form of polyunsaturates. /3-Carotene
and a-carotene were never significantly associated
with polyunsaturated fat levels but tended also to show
a trend toward protection only in the presence of the
highest concentrations of polyunsaturated fats.
Smoking status and carotenoid effects
Stratification by smoking status indicated that the
effect of lycopene among nonsmokers (table 6) was
strongest. ^-Carotene was not protective in any group.
Am J Epidemiol Vol. 146, No. 8, 1997
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TABLE 5. Conditional odds ratios for myocardial infarction and carotenoids by tertile of
polyunsaturated fatty acid (PUFA), EURAMIC Study, 1991-1992*
Adipose tissue sample concentration of
PUFA by tertile (%)
a-Carotene p-Carotene Lycopene
Low, <12.8f
Medium, 12.8-16.0§
High, 16.1-36.211
p for trend*
1.31 (0.67-2.54)$
0.94(0.57-1.54)
0.67(0.36-1.25)
0.02
1.21 (0.73-1.99)
1.14(0.64-2.05)
0.65(0.36-1.18)
0.02
0.71 (0.36-1.40)
0.70(0.38-1.27)
0.38 (0.21-0.71)
0.002
* Conditional on age and center; covariates are body mass index, socioeconomic status, smoking, maternal
and paternal history of disease, and history of high blood pressure. The odds ratios are from controls of the 10th
and 90th percentiles of the carotenoid in the population at large.
t Median PUFA for the low tertile is 11.3% of fat.
i Numbers in parentheses, 95% confidence interval.
§ Median PUFA for the medium tertile is 14.3% of fat.
H Median PUFA for the high tertile is 19.3% of fat.
# Trend test weighted by tertile medians.
TABLE 6. Conditional odds ratios for myocardial infarction and carotenoids by smoking category,
EURAMIC Study, 1991-1992*
Modeled simultaneously
by smoking
Never smoker
Exsmokers
Smokers
a-Carotenet
0.93 (0.49-1.76)H
0.70 (0.38-1.28)
1.28(0.68-2.40)
Adipose tissue concentration of
P-Carotenet
1.14(0.51-2.54)
0.92(0.53-1.59)
0.93(0.61-1.59)
Lycopene§
0.33 (0.13-0.85)
0.41 (0.21-0.83)
0.63(0.39-1.01)
* Conditional on age and center; covariates are body mass index, socioeconomic status, maternal and patemal
history of disease, and history of high blood pressure.
t Median values of a-carotene are 0.10, 0.09, and 0.07 ng/g of fat for never smokers, exsmokers, and
smokers, respectively.
t Median values of p-carotene are 0.50, 0.41, and 0.34 u.g/g of fat for never smokers, exsmokers, and
smokers, respectively.
§ Median values of lycopene are 0.27,0.23, and 0.26 ng/g of fat for never smokers, exsmokers, and smokers,
respectively.
11 Numbers in parentheses, 95% confidence interval.
DISCUSSION
Lycopene is present in the blood in concentrations
roughly equal to those of /3-carotene. For unknown
reasons, certain organs (28) selectively take up or
concentrate lycopene so that tissue levels greatly ex-
ceed those of /3-carotene. Although little is known
about the uptake and turnover of carotenoids in adi-
pose tissue, the adipose tissue levels of lycopene, as
with other carotenoids, are derived largely from the
diet and serve as a better indicator of long-term expo-
sure than do serum or recent dietary records (29). Even
if tissues such as adrenal glands or prostate concen-
trate lycopene, the vast majority of the carotenoids
will be found in the adipose tissue. It is important to
note that lycopene was not available as a supplement
to the individuals in this study prior to their recruit-
ment. Major food sources appear to be tomatoes and
tomato products, watermelon, grapefruit, and seafood
such as lobster and crab. Foods rich in lycopene have
recently been suggested to be inversely associated
with prostate cancer (30). There are indications in the
literature that lycopene is a more potent antioxidant
than /3-carotene. DiMascio et al. (31) showed the
disappearance in vitro of lycopene in cells under sin-
glet oxygen stress to be greater than that of a-carotene,
/3-carotene, and a-tocopherol. A study of the sequen-
tial order of antioxidant consumption in Cu2+-medi-
ated oxidation of low density lipoprotein found that
lycopene was consumed first, with cryptoxanthin and
lutein/zeaxanthin next, and /3-carotene following in
last place (32). Furthermore, it has recently been dis-
covered that skin exposure to ultraviolet radiation un-
der controlled experimental conditions results in a
strong (31-46 percent) and rapid reduction in skin
lycopene levels but in no change in /3-carotene levels
in the skin (33). Thus, lycopene may be the underlying
carotenoid providing antioxidant protection.
Since individuals consuming diets high in vegeta-
bles tend to have higher levels of all carotenoids, the
strong association between lycopene and /3-carotene
Am J Epidemiol Vol. 146, No. 8, 1997
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can conceivably explain the /3-carotene-myocardial in-
farction association evident in some observational
studies. |3-Carotene may be a good marker of lycopene
intake, and its effect disappears when both are consid-
ered simultaneously. In the same line of argument,
lycopene could be a marker of other active phyto-
chemicals in tomatoes and possibly in other major
food sources of this antioxidant. The protective poten-
tial of lycopene was greatest among individuals with
the highest polyunsaturated fat stores, consistent with
an antioxidant effect. The interaction was not, how-
ever, strongest among smokers.
Adipose tissue provides quantitative measures of
prior exposure unbiased by problems of dietary assess-
ment by questionnaire or imprecise food composition
values. It is subject to individual differences in metab-
olism and absorption. Despite these weaknesses, for
components widely distributed in the diet with high
day-to-day variation in intakes—as is the case with
carotenoids—it remains a useful biomarker of expo-
sure. In a case-control study, there is the potential for
the disease condition to affect the biomarker. To pre-
vent this, adipose tissue was used, and aspirations
were done during hospitalization soon after the infarc-
tion. Since adipose tissue is a stable depository of
fat-soluble substances whose turnover tissue is quite
slow (29, 34), and since it was collected shortly after
the infarctions, it is unlikely to be significantly af-
fected by the occurrence of myocardial infarction. In
this case-control design, only patients who survived
until admission to the hospital and until adipose tissue
aspiration were included. This may be a potential
source of bias if the association among the deaths
differs from that in the surviving patients.
Our results are consistent with a protective effect
of adipose tissue levels of lycopene, but not of /3-
carotene or a-carotene, on myocardial infarction risk.
Alternately, lycopene may be a marker of another
protective substance in a common food source. The
protective association with lycopene was not seen in
smokers. It did, however, interact with another major
source of oxidative stress, stores of polyunsaturated
fats, which are markers of consumption of high poly-
unsaturated fat diets. This suggests that lycopene may
be operating under a tissue-specific antioxidant mech-
anism.
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